We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Peter Gibson FRACP, FThorSoc, DMed (Research)

Peter Gibson FRACP, FThorSoc, DMed (Research)

Conjoint Professor, Priority Research Centre for Healthy Lungs, College of Health, Medicine and Wellbeing, University of Newcastle, Hunter Medical Research Institute, Newcastle, Australia; Respiratory Specialist, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia

Peter Gibson works as a doctor who cares for people with respiratory diseases and as a clinical scientist investigating the mechanisms and treatment of asthma, COPD, cough, and other airway disorders.

He is a concept leader who has developed innovative approaches around inflammatory subtypes of asthma and cough; airway biomarkers; neurogenic mechanisms, laryngeal dysfunction and related treatments for refractory cough; multidimensional assessment and management of complex airway disorders such as severe asthma, airways diseases in the elderly, and asthma in pregnant women. Peter led the team that conducted the pivotal RCT establishing the place of macrolides for chronic asthma, and this is now recommended in asthma guidelines.

His peers have awarded Peter several research medals and elected him as the president of the Thoracic Society of Australia and New Zealand (2015-6). He is a senior staff specialist at the John Hunter Hospital in Newcastle, a Conjoint Professor at the University of Newcastle(UON), and former director of the Hunter Medical Research Institute’s VIVA research programme and UON’s PRC for healthy lungs.

His research and clinical practice serve to bring research developments into focus as effective health care interventions that improve the health of people suffering from breathing disorders.

H-index: Google scholar 102, Scopus 95

Publications : according to your track record statement it is >690. UoN profile that pulls from scopus =726


Dr. Gibson reports grants and personal fees from GSK and AstraZeneca, personal fees from Novartis, Chiesi, and Sanofi, outside the submitted work.

Recent Contributions to PracticeUpdate:

  1. Efficacy of Gefapixant in the Treatment of Chronic Cough